Pharmacokinetics (PK)

药代动力学（PK）

• 批准号: 10438621
• 负责人: DUXIN SUN
• 金额: $ 13.88万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10438621
• 关键词: Adopted; Antineoplastic Agents; Applications Grants; Cancer Center; Cancer Center Support Grant; Chemicals; Clinical; Collaborations; Consultations; Data; Development; Developmental Therapeutics Program; Doctor of Philosophy; Drug Kinetics; Electrospray Ionization; Funding; Future; Goals; Grant; Individual; Interdisciplinary Study; Joints; Lead; Legal patent; Maps; Mass Spectrum Analysis; Methods; Pathway interactions; Peer Review Grants; Pharmaceutical Preparations; Pharmacology; Phase; Population; Productivity; Publications; Research; Research Personnel; Resolution; Resource Sharing; Resources; Sampling; Science; Secure; Services; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; System; Techniques; Technology; The Sun; Time; Tissue Sample; Tissue imaging; Tissues; Training; Translations; University of Michigan Comprehensive Cancer Center; anti-cancer therapeutic; anticancer activity; anticancer research; base; cost; dosage; drug development; drug discovery; drug market; drug metabolism; experience; imaging biomarker; innovation; instrument; instrumentation; liquid chromatography mass spectrometry; mass spectrometric imaging; member; novel; operation; pharmacokinetics and pharmacodynamics; phase II trial; phase IV trial; pre-clinical; programs

PROJECT SUMMARY/ABSTRACT (PHARMACOKINETICS) The Pharmacokinetics (PK) Shared Resource (SR) was founded in 2009 and has been funded by the CCSG since 2012. The goal of the PK SR is to provide high quality, cost- and time-efficient services that propel cancer research forward. It uses one-on-one consultations with University of Michigan Comprehensive Cancer Center (UMCCC) members at the start of projects to stimulate innovative research and to support multidisciplinary collaborations. The SR has successfully grown in capability, services, and staffing in order to keep pace with an expanding user base. Since its inception, the PK SR has been led by Duxin Sun, PhD, a skilled investigator with extensive experience in preclinical and clinical PK and drug development. By working closely with UMCCC leaders and members, Dr. Sun and his team have anticipated the changing needs of UMCCC researchers by adopting state-of-the-art technologies and approaches that accelerate the development of novel anticancer therapeutics arising from member research.

项目摘要/摘要（药代动力学）